Colin Bristow
Stock Analyst at UBS
(2.00)
# 3,104
Out of 5,006 analysts
102
Total ratings
38.33%
Success rate
-4.61%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Maintains: Neutral | $108 → $112 | $113.58 | -1.39% | 4 | Aug 8, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $582 → $553 | $402.90 | +37.25% | 15 | Aug 5, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $71 → $80 | $64.81 | +23.44% | 4 | Jul 29, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $12 → $5 | $3.18 | +57.23% | 3 | Jun 17, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $1.2 → $1 | $2.11 | -52.61% | 6 | May 21, 2025 | |
| IMVT Immunovant | Downgrades: Neutral | $38 → $17 | $16.55 | +2.72% | 6 | Apr 22, 2025 | |
| AMGN Amgen | Maintains: Neutral | $315 → $319 | $294.12 | +8.46% | 9 | Apr 14, 2025 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $6 → $4 | $1.94 | +106.19% | 4 | Mar 28, 2025 | |
| ENGN enGene Holdings | Downgrades: Neutral | $34 → $7 | $7.63 | -8.26% | 2 | Feb 14, 2025 | |
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $26.43 | +5.94% | 13 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $120 | $88.80 | +35.14% | 6 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $234 → $202 | $154.05 | +31.13% | 10 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $56 → $16 | $2.55 | +527.45% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $585.48 | +87.71% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $23.26 | +617.97% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $845.05 | -50.30% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $4.61 | -56.62% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $2.90 | +520.69% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $230.19 | -36.57% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $45.14 | +66.15% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $2.28 | +1,040.35% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $5.47 | +64.53% | 1 | Aug 23, 2021 |
Gilead Sciences
Aug 8, 2025
Maintains: Neutral
Price Target: $108 → $112
Current: $113.58
Upside: -1.39%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Buy
Price Target: $582 → $553
Current: $402.90
Upside: +37.25%
PTC Therapeutics
Jul 29, 2025
Maintains: Buy
Price Target: $71 → $80
Current: $64.81
Upside: +23.44%
Rocket Pharmaceuticals
Jun 17, 2025
Maintains: Buy
Price Target: $12 → $5
Current: $3.18
Upside: +57.23%
ALX Oncology Holdings
May 21, 2025
Maintains: Buy
Price Target: $1.2 → $1
Current: $2.11
Upside: -52.61%
Immunovant
Apr 22, 2025
Downgrades: Neutral
Price Target: $38 → $17
Current: $16.55
Upside: +2.72%
Amgen
Apr 14, 2025
Maintains: Neutral
Price Target: $315 → $319
Current: $294.12
Upside: +8.46%
Acumen Pharmaceuticals
Mar 28, 2025
Maintains: Buy
Price Target: $6 → $4
Current: $1.94
Upside: +106.19%
enGene Holdings
Feb 14, 2025
Downgrades: Neutral
Price Target: $34 → $7
Current: $7.63
Upside: -8.26%
Pfizer
Feb 5, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $26.43
Upside: +5.94%
Jan 8, 2025
Maintains: Buy
Price Target: $125 → $120
Current: $88.80
Upside: +35.14%
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $154.05
Upside: +31.13%
Aug 9, 2024
Maintains: Neutral
Price Target: $56 → $16
Current: $2.55
Upside: +527.45%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $585.48
Upside: +87.71%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $23.26
Upside: +617.97%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $845.05
Upside: -50.30%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $4.61
Upside: -56.62%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $2.90
Upside: +520.69%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $230.19
Upside: -36.57%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $45.14
Upside: +66.15%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $2.28
Upside: +1,040.35%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $5.47
Upside: +64.53%